Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin...
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is reasonably priced on P/E.
Target Price
The average target price of 9995.HK is 78 and suggests 9% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to dec
Buy
Sell